DelveInsight’s latest report, “Gout – Market Insight, Epidemiology and Market Forecast – 2032,” integrates robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments, offering valuable insights into the evolving treatment paradigm. The gout market within the 7MM—which includes the United States, EU5 (France, Germany, Italy, Spain, and the UK), and Japan—is projected to show notable growth with a respectable compound annual growth rate (CAGR) by 2032. This growth reflects the rising prevalence of gout, an aging demographic, and innovations in drug delivery systems and personalized medicine approaches.
Download the Gout Market report to understand which factors are driving the gout therapeutic market @ Gout Market Trends.
The report offers an in-depth epidemiological analysis and forecasts through 2032. Gout affects approximately 3-4% of adults in the United States, with men being more commonly affected than women. Moreover, gout prevalence increases with age. it is lowest among individuals aged 20 to 39 years and highest among those aged 80 years or older.
The treatment landscape for gout has evolved markedly, with multiple effective options available for both acute flares and long-term management. Current first-line therapies for acute attacks include nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and corticosteroids. For chronic management, xanthine oxidase inhibitors like allopurinol and febuxostat remain the cornerstone treatments. ZURAMPICIS (AstraZeneca), a urate transporter inhibitor, is also used to treat patients with gout, by removing excess uric acid near joints. It is recommended only as an adjuvant with either allopurinol or febuxostat when these medications are not sufficient.
Discover evolving trends in the gout patient pool forecasts @ Gout Epidemiology Analysis.
DelveInsight’s analysis indicates that several companies are launching clinical trials to explore new gout treatment options or enhance existing ones. The clinical development pipeline for gout includes drugs such as DYV700 (Dyve), AR882 (Arthrosi Therapeutics), DYV700 (Dyve Biosciences), Dapansutrile (Olatec Therapeutics) and XRx-026 (XORTX Therapeutics), among others.
In March 2025, XORTX Therapeutics (NASDAQ: XRTX) announced a Type B meeting with the FDA scheduled for late April 2025 to discuss its proprietary formulation, XRx-026, for gout treatment. Towards the close of March 2025, Shanton Pharma reported positive top-line results from a Phase IIb clinical trial of its investigational gout therapy, SAP-001, targeting patients who are unresponsive to existing treatments. These developments underscore the momentum in the gout treatment landscape.
Furthermore, in January 2025, Scilex Holding Company, a subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), amended its license agreement with RxOmeg Therapeutics LLC (ROMEG) to obtain the exclusive rights to market and distribute GLOPERBA worldwide. Previously, in June 2022, Scilex had received marketing and distribution rights only for the US. GLOPERBA is the first liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Unlock which gout emerging drug is expected to capture the largest market share in 7MM by 2032. Visit the Gout Drug Insights
The evolving landscape of gout treatment reflects significant progress in addressing unmet medical needs through innovative therapies. Emerging biologics, advanced drug delivery systems, and personalized medicine approaches are poised to redefine treatment strategies for both acute flares and chronic disease management. As these therapies gain regulatory approval and enter the market, they hold promise for improved patient outcomes and enhanced quality of life.
Table of Contents
1. Report Introduction
2. Executive Summary of Gout Pain
3. Gout Pain Market Share at a glance
4. Executive Summary of Gout Pain
5. Key Events
6. Gout Epidemiology and Market Methodology
7. Gout Background and Overview
8. Gout Pain Epidemiology and Patient Population
9. Country-Wise: Epidemiology of Gout Pain
10. Patient Journey
11. Gout Marketed Therapies
12. Gout Emerging Therapeutics
13. Market Size of Gout Pain
14. Gout Unmet Needs
15. SWOT Analysis
16. KOL Views
17. Reimbursement and Market Access
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Gout Pipeline Insight
Gout Pipeline Insight provides comprehensive insights about the gout pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the gout companies, including Jiangsu Atom Bioscience and Pharmaceutical, LG Chem, Shanton Pharma, TWi Biotechnology, Olatec Therapeutics, JW Pharmaceutical, Revive Therapeutics, Hinova pharmaceuticals, Arthrosi Therapeutics, Dyve Biosciences, Jiangsu Atom Bioscience and Pharmaceutical, Swedish Orphan Biovitrum, Allen Pharmaceuticals, Teijin Pharma, AstraZeneca, R-Pharm, InventisBio, Sinovent, and Shenyang Sunshine Pharmaceutical, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Arpit AnandEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services
